Skip to Content

Brain and Spine Tumors Clinical Trials

A randomized, Double-blind, Phase II Trial of Surgery, Radiation Theray Plus Temozolomide and Pembroliumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Aims: The purpose of this study is to find out if adding immunotherapy (pembrolizumab) with or without a vaccine (HSPPC-96) to standard of care treatment for GBM improves survival of newly diagnosed GBM subjects. The standard treatment for GBM consists of surgery to remove the brain tumor, radiation and chemotherapy (temozolomide).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-383
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Aims:
The purpose of this Phase III study is to finally attain a clear answer to the long-standing question of which treatment route leads to the best clinical outcome for patients with newly diagnosed WHO grade II meningioma. Subjects will be randomly assigned into one of two groups: Group 1 will be observed following surgery and Group 2 will receive radiation therapy following surgery.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-270
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed Mgmt (Tumor O-6-Methylguanine Dna Methyltransferase) Unmethylated Glioblastoma
Aim: The purpose of the study is to find out whether adding ipilimumab and nivolumab to radiotherapy will significantly prolong progression free survival versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH20-366
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes